Current antiviral combination therapy for chronic hepatitis C patients who failed to interferon alfa-based treatment

Trapero-Marugán, María; Mendoza, Jorge; Monteagudo, José Andrés Moreno; Chaparro, María; Garcı́a-Buey, Luisa; González-Moreno, Leticia; Borque, M.J.; Moreno–Otero, Ricardo

doi:10.1111/j.1365-2710.2010.01231.x

Journal of Clinical Pharmacy and Therapeutics

2010

DOI: 10.1111/j.1365-2710.2010.01231.x

|View full text |Cite

Current antiviral combination therapy for chronic hepatitis C patients who failed to interferon alfa-based treatment

María Trapero-Marugán

Jorge Mendoza

José Andrés Moreno Monteagudo

et al.

Abstract: Retreatment with peginterferon plus ribavirin is an effective option for some chronic hepatitis C non-responder or relapser patients. Higher SVR rate was achieved in relapsers and in those patients who received IFNα monotherapy previously.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2013

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea

Cho¹,

Gwak²,

Paik³

et al. 2013

Gut Liver

View full text Add to dashboard Cite

Background/Aims Pegylated interferon (peginterferon) and ribavirin is the current standard therapy for chronic hepatitis C. The aims of this study were to evaluate the efficacy of peginterferon and ribavirin and to identify predictors of a sustained virological response (SVR) to the retreatment of chronic hepatitis C in Korea.MethodsThe clinical records of 91 patients with chronic hepatitis C who were retreated with peginterferon and ribavirin were retrospectively analyzed. None of the patients had previously attained a SVR, and the patients were categorized according to their previous responses (nonresponder, relapser, or inadequate treatment) to conventional interferon/ribavirin.ResultsThe overall SVR rate was 54.9%. Independent predictors of a SVR were genotypes 2 and 3, relapse, an adherence to peginterferon of over 80%, and an early virological response (EVR). For genotype 1 patients, an adherence to peginterferon of over 80% was an independent predictor of a SVR.ConclusionsPeginterferon and ribavirin therapy is effective for the retreatment of Korean chronic hepatitis C patients who have failed interferon/ribavirin, especially in patients with genotypes 2 and 3, relapse, an adherence to peginterferon over 80%, and an EVR. For genotype 1 patients, retreatment was effective in patients with an adherence to peginterferon over 80%.

show abstract

Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea

Cho¹,

Gwak²,

Paik³

et al. 2013

Gut Liver

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Current antiviral combination therapy for chronic hepatitis C patients who failed to interferon alfa-based treatment

Abstract: Retreatment with peginterferon plus ribavirin is an effective option for some chronic hepatitis C non-responder or relapser patients. Higher SVR rate was achieved in relapsers and in those patients who received IFNα monotherapy previously.

Cited by 1 publication

References 38 publications

Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea

Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea

Contact Info

Product

Resources

About